/DBVT
DBVT Stock - DBV Technologies S.A.
Healthcare|BiotechnologyNASDAQ
$22.76+5.76%
+$1.24 (+5.76%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+83.8%upside
Target: $41.83
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DBVT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$22.53 – $22.99
TARGET (TP)$41.83
STOP LOSS$20.94
RISK/REWARD1:10.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.50
52W High$26.18
52W Low$2.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $15.73M | $4.80M | $5.71M | $11.28M |
| Gross Profit | $-6,813,942 | $15.73M | $-15,499,000 | $-3,565,000 | $11.28M |
| Gross Margin | N/A | 100.0% | -322.9% | -62.5% | 100.0% |
| Operating Income | $-120,526,718 | $-76,432,000 | $-96,631,000 | $-98,614,000 | $-158,842,000 |
| Net Income | $-113,716,769 | $-72,726,000 | $-96,300,000 | $-97,809,000 | $-159,555,000 |
| Net Margin | N/A | -462.4% | -2006.3% | -1713.5% | -1415.0% |
| EPS | $-5.90 | $-3.80 | $-6.20 | $-8.90 | $-14.75 |
Company Overview
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
1
20%
Sell / Underperform
2
40%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$21
Average Target
↓ 5.8% Downside
Now
$2
Low
$21
Average
$42
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | Cantor Fitzgerald | Initiation | Overweight | $42 |
| December 3rd 2025 | Guggenheim | Initiation | Buy | $35 |
| May 29th 2025 | Goldman | Resumed | Sell | $7.25 |
| January 4th 2023 | Societe Generale | Upgrade | Buy | - |
| December 16th 2022 | Goldman | Downgrade | Sell | - |
| May 10th 2022 | Goldman | Downgrade | Neutral | $1.5← $6 |
Earnings History & Surprises
DBVTBeat Rate
68%
Last 19 quarters
Avg Surprise
-4.8%
EPS vs Estimate
Beats / Misses
13/4
2 met exactly
Latest EPS
$-1.20
Q4 2025
EPS Surprise History
Q1 24
+62.5%
$-0.12vs$-0.32
Q2 24
+36.4%
$-1.40vs$-2.20
Q3 24
-30.8%
$-1.70vs$-1.30
Q4 24
+57.9%
$-0.80vs$-1.90
Q1 25
+40.0%
$-1.20vs$-2.00
Q2 25
-8.3%
$-0.26vs$-0.24
Q3 25
-638.1%
$-1.55vs$-0.21
Q4 25
+17.2%
$-1.20vs$-1.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 10, 2026 | $-1.30 | — | — | — |
Q4 2025 | Oct 28, 2025 | $-1.45 | $-1.20 | +17.2% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $-0.21 | $-1.55 | -638.1% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-2.00 | $-1.20 | +40.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.90 | $-0.80 | +57.9% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $-1.30 | $-1.70 | -30.8% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-2.20 | $-1.40 | +36.4% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.32 | $-0.12 | +62.5% | ✓ BEAT |
Q4 2023 | Oct 31, 2023 | $-0.30 | $-0.18 | +40.0% | ✓ BEAT |
Q3 2023 | Jul 31, 2023 | $-0.26 | $-0.26 | 0.0% | = MET |
Q2 2023 | May 4, 2023 | $-0.50 | $-0.22 | +56.0% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-2.30 | $-2.30 | 0.0% | = MET |
Q4 2022 | Nov 3, 2022 | $-0.32 | $-0.18 | +43.8% | ✓ BEAT |
Q3 2022 | Aug 1, 2022 | $-1.70 | $-1.80 | -5.9% | ✗ MISS |
Q2 2022 | May 2, 2022 | $-4.70 | $-1.50 | +68.1% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.64 | $-0.26 | +59.4% | ✓ BEAT |
Q4 2021 | Oct 26, 2021 | $-2.90 | $-2.20 | +24.1% | ✓ BEAT |
Q3 2021 | Aug 2, 2021 | $-6.40 | $-2.80 | +56.3% | ✓ BEAT |
Q2 2021 | May 3, 2021 | $-3.90 | $-2.70 | +30.8% | ✓ BEAT |
Latest News
HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $40
📈 PositiveBenzinga•Dec 17, 2025, 03:10 PM
Cantor Fitzgerald Maintains Overweight on DBV Technologies, Raises Price Target to $48
📈 PositiveBenzinga•Dec 17, 2025, 02:57 PM
DBV Technologies shares are trading higher after the company announced topline results from the Phase 3 VITESSE trial met its primary endpoint.
📈 PositiveBenzinga•Dec 17, 2025, 02:03 PM
Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $45
📈 PositiveBenzinga•Dec 17, 2025, 01:05 PM
Guggenheim Maintains Buy on DBV Technologies, Raises Price Target to $51
📈 PositiveBenzinga•Dec 17, 2025, 12:53 PM
DBV Technologies surges on Phase 3 trial win for peanut allergy therapy
📈 PositiveSeeking Alpha•Dec 17, 2025, 11:56 AM
Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 16, 2025, 09:30 PM
DBV Technologies Announces Topline Results From Phase 3 VITESSE Trial of VIASKIN Peanut Patch In Peanut Allergic Children Aged 4-7 Years; VITESSE Met Its Primary Endpoint
📈 PositiveBenzinga•Dec 16, 2025, 09:07 PM
Trading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 16, 2025, 09:01 PM
HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $35
📈 PositiveBenzinga•Dec 15, 2025, 11:46 AM
Cantor Fitzgerald Initiates Coverage On DBV Technologies with Overweight Rating, Announces Price Target of $42
📈 PositiveBenzinga•Dec 15, 2025, 11:33 AM
Guggenheim Initiates Coverage On DBV Technologies with Buy Rating, Announces Price Target of $35
📈 PositiveBenzinga•Dec 3, 2025, 04:01 PM
Reported Earlier, DBV Technologies Confirms Completion Of Phase 3 Treatment Phase For VIASKIN Peanut Patch With Topline Data Expected In Q4 2025
➖ NeutralBenzinga•Nov 12, 2025, 06:53 AM
Reported Earlier, DBV Technologies Announces $30M ADS Sale Under Nasdaq ATM Program, Cash Runway Now Extended To End Of 2026
📈 PositiveBenzinga•Oct 30, 2025, 08:29 AM
HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $20
📈 PositiveBenzinga•Oct 29, 2025, 05:46 PM
DBV Technologies shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Oct 29, 2025, 01:02 PM
DBV Technologies Q3 EPS $(0.24) Beats $(0.76) Estimate, Sales $2.774M Beat $655.000K Estimate
📈 PositiveBenzinga•Oct 28, 2025, 08:47 PM
DBV Technologies Launches $150M At-The-Market Offering Program
📉 NegativeBenzinga•Sep 5, 2025, 08:34 PM
Frequently Asked Questions about DBVT
What is DBVT's current stock price?
DBV Technologies S.A. (DBVT) is currently trading at $22.76 per share. The stock has moved +5.76% today.
What is the analyst price target for DBVT?
The average analyst price target for DBVT is $41.83, based on 1 analyst.
What sector is DBV Technologies S.A. in?
DBV Technologies S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DBVT's market cap?
DBV Technologies S.A. has a market capitalization of $0.54 billion, making it a small-cap company.
Does DBVT pay dividends?
No, DBV Technologies S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
LXEO
Lexeo Therapeutics, Inc. Common Stock
$10.35
Mkt Cap: $0.8B
Explore stocks similar to DBVT for comparison